PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to

bstitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete if Known				
Application Number	10/669,869-Conf. #5138			
Filing Date	September 23, 2003			
First Named Inventor	Cyrus R. Kumana			
Art Unit	1616			
Examiner Name	F.I. Choi			
Attorney Docket Number	V9661.0072			

		NON PATENT LITERATURE DOCUMENTS	,		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т		
FC		AU, WING-YAN et al., "Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia", <i>Blood</i> 102(1):407-408 (July 1, 2003)			
		AU, WING Y. et al., "Treatment of Relapsed Acute Promyelocytic Leukemia by Arsenic-Based Strategies without Hematopoietic Stem Cell Transplantation in Hong Kong: A Seven-Year Experience". Blood (ASH Annual Meeting Abstracts), 104:Abstract 395 (2004)			
		AU, WING-YAN et al., "Successful Treatment of Relapsed Acute Promyelocytic Leukemia in a Patient Receiving Continuous Ambulatory Peritoneal Dialysis With Oral Arsenic Trioxide", Arch Intern Med., 165:1067-1068 (2005)			
		AU, WING-YAN et al., "Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia", <i>Blood</i> , 107(7):3012-3013 (2006)			
		KUMANA, C.R. et al., "Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies", Eur J Clin Pharmacol, 58:521-526 (2002)			
FC		SIU, CHUNG-WAH et al., "Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications on long-term cardiac safety", <i>Blood</i> , 0:2006-01-0054 (2006)			
			H		
		·	├		
			_		
			-		
			┝		
			$oxed{oldsymbol{oldsymbol{eta}}}$		
			-		
			-		
			 		
			_		
			-		
			-		
			-		
			-		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

Examiner	/Frank Choi/	Date	02/01/2007
Signature	,	Considered	02/01/2007